ClinicalTrials.gg
TerminatedNCT00437671Updated Jan 20, 2016

Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels

A Phase 4 interventional study of Tetanus Immune Globulin (Human) and Diphtheria-Tetanus Toxoids Adsorbed in Tetanus, sponsored by Grifols Therapeutics LLC. Terminated at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-20.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 4, Interventional, and Prevention

Why this study was terminated
Study terminated for cGCP non-compliance. Analyses could not be performed.
Phase
Phase 4
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The goal of this study is to re-evaluate the tetanus antibody pharmacokinetic profile when Tetanus Immune Globulin (Human)(TIG) and Tetanus vaccine (Tetanus toxoid; TT) are given concurrently with strict control on the anatomical location and timing of administration of TIG and TT. Pharmacokinetic profile of antibody titer including the duration of adequate titer protection provided by TIG and TT given in combination will be assessed using a standardized administration regimen and standardized antibody assay procedure. This study may provide evidence for the recommendations of the World Health Organisation (WHO) whereby dual coverage with both a vaccine and tetanus hyperimmune would ideally provide the best coverage for anyone with the potential of developing tetanus.

Read the detailed description

This is a prospective, open-label, single-center trial including a single group of subjects with no known primary immunization history with TT or >10 years have passed since the last dose of tetanus containing vaccine was received. The study will enroll six subjects who would receive both dT and TIG concurrently on Day 1.

All dosed subjects will be followed for 40 days during which Day 1, 2, 3, 4, 5, 7, 14, 21, 30 and 40 time levels of tetanus antibodies will be measured in order to determine the serum level vs. time curve, Cmax, Tmax, and duration of protective antibody levels.

02

Conditions studied

  • Tetanus

Browse trials for

Keywords

  • trismus
  • lockjaw
03

In context

Tetanus

206 studies on the registry are indexed under Tetanus; 22 are open to participants now.

This study's enrollment of 6 is below the median of 400 across 178 interventional studies indexed under Tetanus.

Browse Tetanus studies →

Lead sponsor

Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.

First submitted before Grifols Therapeutics LLC became part of Grifols.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 90 years.
  • Signed a written informed consent prior to initiation of any study-related procedures.
  • No known primary immunization history with TT/dT or >10 years have passed since the last dose of tetanus containing vaccine was received. Subjects with unknown or uncertain previous vaccination histories are considered to have no previous tetanus and toxoid doses. Subjects who have had military service since 1941 will be considered to have had 1 dose of tetanus vaccine.
  • Subjects must have documented tetanus antibody levels that are non-protective levels (\< 0.15 IU/ml).
  • Subjects must be free of any presenting wound or wound infection

Exclusion criteria

Exclusion Criteria:

  • History or suspicion of significant allergic reaction to intravenous immune globulin, and or blood products
  • A history of selective IgA deficiency (serum level \<5.0 mg/dL) and known antibodies to IgA
  • Congestive heart failure (New York Association stage greater than Class II)
  • Conditions whose symptoms and effects could alter protein catabolism and/or IgG utilization (e.g. protein-losing enteropathies, nephrotic syndrome)
  • Women of child bearing potential who do not practice adequate contraception (i.e. chemical or mechanical methods) and pregnant or lactating females
  • Subjects who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections
  • TIG therapy within the previous six months
  • Investigational drug therapy within the previous three months
  • History of Thromboembolism
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Entered study

    Drug: Tetanus Immune Globulin (Human) · Biological: Diphtheria-Tetanus Toxoids Adsorbed

Interventions

  • DrugTetanus Immune Globulin (Human)

    Based on package insert recommendation and recommendations of WHO

    Also known as: HyperTET S/D, BayTet, BAY 19-8515, TAL-05-00013, NDC 13533-634-02

  • BiologicalDiphtheria-Tetanus Toxoids Adsorbed

    Based on package insert recommendations and recommendations of WHO

06

What researchers measure

Primary outcomes

  1. Antibody titer serum level at each time point

    Time frame: 40 days

  2. Cmax

    Time frame: 40 days

  3. Tmax

    Time frame: 40 days

07

Study locations

1 site
  • Long Island Jewish Medical Center
    New Hyde Park, New York 11040, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2007
First posted
Feb 21, 2007
Start
Mar 2007
Primary completionActual
Sep 2007
CompletionActual
Sep 2007
Last update
Jan 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00437671
Responsible party
Sponsor
First posted
Feb 21, 2007
Start date
Mar 2007
Primary completion
Sep 2007
Completion
Sep 2007
Last update
Jan 20, 2016

Study contacts

Kumar Alagappan, MD
principal investigator · Long Island Jewish Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion